Quest Diagnostics (NYSE:DGX) Price Target Raised to $190.00

Quest Diagnostics (NYSE:DGX) had its price target increased by research analysts at JPMorgan Chase & Co. from $180.00 to $190.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 7.03% from the company’s previous close.

A number of other equities research analysts have also weighed in on DGX. Barclays lifted their target price on shares of Quest Diagnostics from $175.00 to $185.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 23rd. Redburn Partners set a $195.00 target price on Quest Diagnostics in a research report on Wednesday, April 2nd. Piper Sandler lifted their price target on Quest Diagnostics from $180.00 to $200.00 and gave the company a “neutral” rating in a research report on Monday, April 28th. UBS Group lifted their price target on shares of Quest Diagnostics from $166.00 to $170.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Finally, Citigroup cut shares of Quest Diagnostics from a “buy” rating to a “neutral” rating and set a $185.00 price objective on the stock. in a report on Tuesday, March 4th. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $185.73.

Quest Diagnostics Trading Down 0.2 %

NYSE:DGX opened at $177.52 on Tuesday. The firm has a market capitalization of $19.82 billion, a P/E ratio of 23.08, a P/E/G ratio of 2.16 and a beta of 0.52. The company has a quick ratio of 1.02, a current ratio of 1.10 and a debt-to-equity ratio of 0.82. The company has a fifty day moving average of $169.51 and a 200 day moving average of $162.36. Quest Diagnostics has a 52 week low of $135.35 and a 52 week high of $179.32.

Quest Diagnostics (NYSE:DGX) last posted its earnings results on Tuesday, April 22nd. The medical research company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $2.15 by $0.06. The company had revenue of $2.65 billion during the quarter, compared to analyst estimates of $2.63 billion. Quest Diagnostics had a net margin of 8.80% and a return on equity of 15.07%. On average, research analysts predict that Quest Diagnostics will post 9.7 earnings per share for the current year.

Insider Activity

In other Quest Diagnostics news, Director Vicky B. Gregg sold 1,250 shares of the business’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $164.57, for a total transaction of $205,712.50. Following the completion of the sale, the director now directly owns 16,867 shares in the company, valued at $2,775,802.19. The trade was a 6.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Mark E. Delaney sold 403 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $164.30, for a total transaction of $66,212.90. Following the completion of the transaction, the senior vice president now owns 4,624 shares in the company, valued at $759,723.20. This trade represents a 8.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,903 shares of company stock valued at $9,460,221 over the last ninety days. 8.16% of the stock is currently owned by corporate insiders.

Institutional Trading of Quest Diagnostics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BankPlus Wealth Management LLC purchased a new stake in shares of Quest Diagnostics in the 4th quarter worth $355,000. Van ECK Associates Corp increased its position in Quest Diagnostics by 980.3% in the fourth quarter. Van ECK Associates Corp now owns 24,198 shares of the medical research company’s stock worth $3,650,000 after buying an additional 21,958 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in shares of Quest Diagnostics in the fourth quarter worth about $54,000. Clean Yield Group lifted its position in shares of Quest Diagnostics by 17.7% during the 4th quarter. Clean Yield Group now owns 26,428 shares of the medical research company’s stock valued at $3,987,000 after buying an additional 3,983 shares in the last quarter. Finally, SVB Wealth LLC bought a new position in shares of Quest Diagnostics during the 4th quarter valued at approximately $10,345,000. 88.06% of the stock is owned by hedge funds and other institutional investors.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.